US Food and Drug Administration Approval of New Drugs Based on Noninferiority Trials in Oncology

This Viewpoint highlights the drawbacks of US Food and Drug Administration approval of lenvatinib for unresectable hepatocellular cancer based on the results of a noninferiority trial.

Read the full article here

Related Articles